MedTrace Logo

Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19

NCT04805671 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 399

Last updated 2024-02-06

Study results available
· View outcomes & findings →

Summary

This placebo controlled study is intended to generate safety and efficacy data in order to provide a treatment option for COVID-19 in patients with a high risk of disease progression based on age or co-morbid medical conditions.

Conditions

Interventions

DRUG

ADG20

Single dose of ADG20

DRUG

Normal saline

Single dose of normal saline

Sponsors & Collaborators

  • Invivyd, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-26
Primary Completion
2022-02-10
Completion
2022-11-03
FDA Drug
Yes

Countries

  • Argentina
  • Brazil
  • Bulgaria
  • Germany
  • Greece
  • Hungary
  • Moldova
  • Poland
  • Romania
  • South Africa
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04805671 on ClinicalTrials.gov